Optical Coherence Tomography Angiography Metrics Monitor Severity Progression of Diabetic Retinopathy-3-Year Longitudinal Study
- PMID: 34070479
- PMCID: PMC8197493
- DOI: 10.3390/jcm10112296
Optical Coherence Tomography Angiography Metrics Monitor Severity Progression of Diabetic Retinopathy-3-Year Longitudinal Study
Abstract
To examine retinal vessel closure metrics and neurodegenerative changes occurring in the initial stages of nonproliferative diabetic retinopathy (NPDR) and severity progression in a three-year period. Methods: Three-year prospective longitudinal observational cohort of individuals with type 2 diabetes (T2D), one eye per person, using spectral domain-optical coherence tomography (SD-OCT) and OCT-Angiography (OCTA). Eyes were examined four times with one-year intervals. OCTA vessel density maps of the retina were used to quantify vessel closure. Thickness of the ganglion cell + inner plexiform layer (GCL + IPL) was examined to identify retinal neurodegenerative changes. Diabetic retinopathy ETDRS classification was performed using the seven-field ETDRS protocol. Results: A total of 78 eyes/patients, aged 52 to 80 years, with T2D and ETDRS grades from 10 to 47 were followed for 3 years with annual examinations. A progressive increase in retinal vessel closure was observed. Vessel density (VD) showed higher decreases with retinopathy worsening demonstrated by step-changes in ETDRS severity scale (p < 0.001). No clear correlation was observed between neurodegenerative changes and retinopathy progression. Conclusions: Retinal vessel closure in NPDR correlates with DR severity progression. Our findings provide supporting evidence that OCTA metrics of vessel closure may be used as a surrogate for DR severity progression.
Keywords: OCTA; diabetes; ischemia; retinopathy; severity.
Conflict of interest statement
I.P.M., T.S., L.M., M.H.M., D.T., A.R.S. and C.L. declare no conflict of interests. Disclosures: S.K., L.d.S., W.L. and M.K.D. are employees of Carl Zeiss Meditec; J.C.-V. reports grants from Carl Zeiss Meditec and is a consultant for Alimera Sciences, Allergan, Bayer, Gene Signal, Novartis, Pfizer, Precision Ocular Ltd., Roche, Sanofi-Aventis, Vifor Pharma, and Carl Zeiss Meditec.
Figures

References
-
- Cunhavaz J.G., Bernardes R., Santos T., Oliveira C., Lobo C., Pires I., Ribeiro L. Computer-Aided Detection of Diabetic Retinopathy Progression. Digit. Teleretinal Screen. 2012;226:59–66. doi: 10.1007/978-3-642-25810-7_6. - DOI
Grants and funding
LinkOut - more resources
Full Text Sources
Medical